Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7654)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 15, 2016 (publication date) through May 6, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Tsuchikawa T, Takeuchi S, Nakamura T, Shichinohe T, Hirano S. Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer. World J Gastrointest Oncol 2016; 8(11): 786-792 [PMID: 27895816 DOI: 10.4251/wjgo.v8.i11.786] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v8/i11/786.htm |
| Number | Citing Articles |
| 1 |
Zhenfeng Shi, Jifang Liu, Lei Tian, Jingyi Li, Yue Gao, Yue Xing, Wenjing Yan, Chenyu Hua, Xiaolin Xie, Chang Liu, Chengyuan Liang. Insights into stimuli-responsive diselenide bonds utilized in drug delivery systems for cancer therapy. Biomedicine & Pharmacotherapy 2022; 155: 113707 doi: 10.1016/j.biopha.2022.113707
|
| 2 |
Reetu Mukherji, Dipanjan Debnath, Marion L. Hartley, Marcus S. Noel. The Role of Immunotherapy in Pancreatic Cancer. Current Oncology 2022; 29(10): 6864 doi: 10.3390/curroncol29100541
|
| 3 |
Yongping Zhou, Qian Wei, Junsheng Fan, Sijin Cheng, Wenzhou Ding, Zhiyuan Hua. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patients. Clinica Chimica Acta 2018; 479: 181 doi: 10.1016/j.cca.2018.01.024
|
| 4 |
Carl J. DeSelm, Zachary E. Tano, Anna M. Varghese, Prasad S. Adusumilli. CAR T‐cell therapy for pancreatic cancer. Journal of Surgical Oncology 2017; 116(1): 63 doi: 10.1002/jso.24627
|
| 5 |
Abhishek D. Garg, Sanket More, Nicole Rufo, Odeta Mece, Maria Livia Sassano, Patrizia Agostinis, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. OncoImmunology 2017; 6(12): e1386829 doi: 10.1080/2162402X.2017.1386829
|
| 6 |
Andreas Henriksen, Anne Dyhl-Polk, Inna Chen, Dorte Nielsen. Checkpoint inhibitors in pancreatic cancer. Cancer Treatment Reviews 2019; 78: 17 doi: 10.1016/j.ctrv.2019.06.005
|
| 7 |
Chen Liu, He Cheng, Guopei Luo, Yu Lu, Kaizhou Jin, Meng Guo, Quanxing Ni, Xianjun Yu. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. International Journal of Oncology 2017; 51(2): 686 doi: 10.3892/ijo.2017.4032
|
| 8 |
L.C. Cutmore, N.F. Brown, D. Raj, S. Chauduri, P. Wang, J. Maher, Y. Wang, N.R. Lemoine, J.F. Marshall. Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma. Pancreatology 2020; 20(3): 394 doi: 10.1016/j.pan.2020.02.006
|
| 9 |
Xinming Yun, Qin Zhang, Yulai Fang, Changjun Lv, Qingyong Chen, Yuyao Chu, Yanrong Zhu, Zhifeng Wei, Yufeng Xia, Yue Dai. Madecassic acid alleviates colitis-associated colorectal cancer by blocking the recruitment of myeloid-derived suppressor cells via the inhibition of IL-17 expression in γδT17 cells. Biochemical Pharmacology 2022; 202: 115138 doi: 10.1016/j.bcp.2022.115138
|
| 10 |
Tianqi Su, Bo Yang, Tianren Gao, Tongjun Liu, Jiannan Li. Polymer nanoparticle-assisted chemotherapy of pancreatic cancer. Therapeutic Advances in Medical Oncology 2020; 12: 175883592091597 doi: 10.1177/1758835920915978
|
| 11 |
Skaiste Tulyte, Dainius Characiejus, Reda Matuzeviciene, Ausra Janiulioniene, Mantas Radzevicius, Elena Jasiunaite, Tadas Zvirblis, Audrius Sileikis. Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine. International Immunopharmacology 2023; 115: 109722 doi: 10.1016/j.intimp.2023.109722
|